CBX3 and melanoma: Our data underscore the fact that LEF-1 and IL-21R are requisite for the persistence of Cbx3/HP1γ-deficient CD8+ effector T cells in tumors with varied mutation loads that are ICB responsive (B16 melanoma) or non-responsive (ovarian and NBL).